美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ABBV近 30 天 32 則 · 第 1 / 1 頁
- AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?
- AbbVie (ABBV) 公布 VRAYLAR 在真實世界與兒童照護的新數據AbbVie (ABBV) Unveiled New VRAYLAR Data In Real World And Pediatric Care
- What Would It Take For Eli Lilly Stock To Keep Climbing?
- Is Johnson & Johnson Stock Expensive, Or Is STELARA Hiding The Real Price?
- Merck Stock Nearly Doubled Without A Change In Its Revenue Growth
- 艾伯維的股利成長依然穩健，儘管殖利率中等AbbVie’s Dividend Growth Remains Solid Despite a Moderate Yield
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
- 艾伯維在 2026 年精神醫學大會強調支持 VRAYLAR® (cariprazine) 療效的新真實世界數據AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
- 5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income
- Can Volume Keep Covering Eli Lilly's Price Cuts?
- How Large Does Your Portfolio Need to Be to Generate $10,600 a Month?
- AbbVie Stock Just Posted a 74% Response Rate in Myeloma. Here’s What It Means for the Stock in 2026
- 艾伯維將在 2026 年國際骨髓瘤學會(IMS)會議上發表 Etentamig 第三期試驗結果及廣泛多發性骨髓瘤產品線數據AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
- What Happens To AbbVie Stock If SKYRIZI Slows Down?
- 愛力根美學發表新臨床數據 評估服用醫療減重藥物者的皮膚品質改善情形Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
- AbbVie (ABBV) Stock Looks Undervalued On Future Cash Flow
- Is Pfizer's New Business Big Enough To Carry The Old One?
- Should You Judge JNJ Stock Without STELARA?
- How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
- Is AbbVie the Best Dividend King to Buy in September?
- Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
- Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
- AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline
- AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
- AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
- AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
- Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
- ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
- AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
- ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
- Top Analyst Reports for Amazon, AbbVie & Alibaba
- Aging Population Drives Healthcare Growth: Stocks to Watch
- Following Heightened Competition from Botox, Xeomin, and Long-Acting Daxxify, New Study Evaluates Dysport (abobotulinumtoxinA) Revenue Trajectory Through 2034
- AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
- The Zacks Analyst Blog Highlights Applied Materials, Mastercard, AbbVie, INNOVATE and BranchOut
- Top Research Reports for Applied Materials, Mastercard & AbbVie
- H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
- AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
- Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
- Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
- Top Analyst Reports for Microsoft, AbbVie & BHP
- AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。